on SENSORION (EPA:ALSEN)
Sensorion unveils details of the SENS-601 Program Day
On September 18, 2026, Sensorion, a biotechnology company specializing in the treatment of hearing loss disorders, announced the connection information for its SENS-601 Program Day, which will take place on September 22, 2026. This event will highlight the SENS-601 program, a gene therapy targeting the GJB2 gene.
The day will include discussions on the science behind the program, the patient population involved, and details of the HearConnex trial. Experts such as Professor Christine Petit and Dr. Sharon Cushing will lead the discussions. Prior registration is required for the webcast at 2:30 p.m. CET (8:30 a.m. ET).
A replay of the event will be available on the Sensorion website. Further information, including the program, can be found at www.sensorion.com.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SENSORION news